In Vitro Removal of Beta-2-Microglobulin From Uremic Blood With an Immunoadsorption Wall

被引：4

作者：

Yang, Tsung-Hua ^{[1
]}

Lin, Bo-Jhou ^{[1
]}

Ma, Yi-Ling ^{[2
]}

Chou, Kang-Ju ^{[2
]}

机构：

[1] Cheng Shiu Univ, Dept Chem & Mat Engn, Kaohsiung 83347, Taiwan

[2] Kaohsiung Vet Gen Hosp, Div Nephrol, Kaohsiung, Taiwan

来源：

ARTIFICIAL ORGANS | 2012年 / 36卷 / 01期

关键词：

Hemodialysis; beta-2-microglobulin; Immunoadsorption wall; Partially incomplete two-stage polymerization; Pseudo-nephron; Activated clotting time; DIALYSIS-RELATED AMYLOIDOSIS; WHOLE-BLOOD; KIDNEY-TRANSPLANTATION; HEMODIALYSIS-PATIENTS; ARTIFICIAL ORGANS; STATIONARY-PHASE; BIOCOMPATIBILITY; BETA(2)-MICROGLOBULIN; THERAPY; AUTOANTIBODIES;

D O I：

10.1111/j.1525-1594.2011.01294.x

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Dialysis-related amyloidosis (DRA), caused by the accumulation of beta-2-microglobulin (beta-2M), remains a major concern in long-term renal replacement therapies. For years, we have developed an immunoadsorption wall (iWall) for the removal of beta-2M. In this study, we employed a new approach taking advantage of the melting of a buffer ice rod to improve the conditions associated with the manufacturing of an iWall and tested its performance with uremic serum and blood. The preliminary results reveal that the present iWalls thus prepared not only possess the superior properties of affinity and specificity but also show structural stability and acceptable hemocompatibility. We believe that this breakthrough might provide a promising path to successful treatment of DRA as well as establish a useful platform for studying removal of certain pathological toxins accumulated in the blood.

引用

页码：78 / 86

页数：9

共 39 条

[1] A novel immunoadsorption device for removing β2-microglobulin from whole blood [J].

Ameer, GA ;

Grovender, EA ;

Ploegh, H ;

Ting, D ;

Owen, WF ;

Rupnick, M ;

Langer, R .

KIDNEY INTERNATIONAL, 2001, 59 (04) :1544-1550

[2] DALI apheresis in hyperlipidemic patients:: Biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood [J].

Bosch, T ;

Lennertz, A ;

Schmidt, B ;

Fink, E ;

Keller, C ;

Toepfer, M ;

Dräger, J ;

Samtleben, W .

ARTIFICIAL ORGANS, 2000, 24 (02) :81-90

[3] Nontransplant therapy for dialysis-related amyloidosis [J].

Copley, JB ;

Lindberg, JS .

SEMINARS IN DIALYSIS, 2001, 14 (02) :94-98

[4] Intraorbital polyacrylamide gel injection for the treatment of anophthalmic enophthalmos [J].

da Silva, Andre L. Borba ;

Bredemeier, Markus ;

Gebrim, Eloisa S. ;

Moura, Euripedes da M. .

OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2008, 24 (05) :367-371

[5]

de Francisco Angel L M, 2006, Hemodial Int, V10 Suppl 1, pS19

[6] Beta2-Microglobulin [J].

Drueke, Tilman B. ;

Massy, Ziad A. .

SEMINARS IN DIALYSIS, 2009, 22 (04) :378-380

[7]

Floge J, 1988, Contrib Nephrol, V61, P27

[8] Current clinical and pathogenetic understanding of β2-m amyloidosis in long-term haemodialysis patients [J].

Gejyo, F ;

Narita, I .

NEPHROLOGY, 2003, 8 :S45-S49

[9] Single-chain antibody fragment-based adsorbent for the extracorporeal removal of β2-microglobulin [J].

Grovender, EA ;

Kellogg, B ;

Singh, J ;

Blom, D ;

Ploegh, H ;

Wittrup, KD ;

Langer, RS ;

Ameer, GA .

KIDNEY INTERNATIONAL, 2004, 65 (01) :310-322

[10] ACTIVATED COAGULATION TIME OF WHOLE BLOOD [J].

HATTERSLEY, PG .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1966, 196 (05) :436-+

← 1 2 3 4 →